Clinical Trials

The purpose of this study is to determine if a mobile application used to label stools according to the Bristol Stool Scale can safely assist subjects with lactulose titration and lead to decreased rates of hepatic encephalopathy. Additionally, to assess patient willingness to interact with mobile application in taking pictures of bowel movements.

The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.

The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.

Hepatic encephalopathy (HE) is a serious complication of cirrhotic stage liver disease. It is reported that 30-70% of all patients with cirrhosis have HE. The current diagnostic methodology for HE includes a blood lab monitoring of ammonia and neuropsychometric testing, which can define the diagnosis but cannot assess the vitally important daily variability of this complication.

There are, however, distinct cognitive neurologic findings in HE that could be mapped and exploited for quick and accurate daily assessment. Vocal changes and speech analysis may provide guidance in the diagnosis and management of HE. The computer algorithm calculating vocal changes in HE would be ...

early detection of hepatic encephalopathy

The purpose of this study is to assess the effectiveness and safety of rifaximin SSD-40IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites. Participants who have cirrhosis determined by histopathological evidence, transient elastography or presence of esophageal varices, and who have not previously experienced OHE, spontaneous bacterial peritonitis (SBP), esophageal variceal bleeding (EVB), or acute kidney injury-hepatorenal syndrome (AKI-HRS) will be enrolled in the study. 

The purose of this study is to assess the effectiveness and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

The purpose of this study is to identify the clinical characteristics, the management and the outcomes of acute kidney injury (AKI) in patients with cirrhosis worldwide. Additionally, to establish the severity of AKI across different regions, to identify precipitants of AKI across different centers, to identify the phenotypes of AKI across different centers, to evaluate differences in the management of AKI across different centers and their impact on clinical outcomes, and to assess outcomes of acute kidney injury (resolution of AKI, in-hospital mortality, 28-day mortality, 90-day mortality).